

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL				
OMB Number:	3235-0104			
Estimated averag				
nours per respons	se 0.5			

#### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)											
1. Name and Address of Reporting Person* BVF GP HOLDINGS LLC	Stateme	2. Date of Event Requiring Statement (Month/Day/Year) 03/13/2020			ier Name <b>an</b> IA Corp [	d Ticker or Trad XOMA]	ing Symbol				
(Last) (First) (Middle) 44 MONTGOMERY ST., 40TH FLO				4. Relationship of Reporting Person(s) to Issuer				5. If Amendment, Date Original Filed(Month/Day/Year)			
(Street) SAN FRANCISCO, CA 94104					(Check all applicable)  Director			6. Individual or Joint/Group FilingCheck Applicable Line)  Form filed by One Reporting Person  X Form filed by More than One Reporting Person			
(City) (State) (Zip)			Table I	- Non	-Derivati	ive Securities	Beneficially Owned				
1.Title of Security (Instr. 4)		2. Amount of Securities Beneficially Owned (Instr. 4)  3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)  4. Nature of Indirect Beneficial (Instr. 5)				lirect Beneficial Ownership					
Common Stock, \$0.0075 par value per	share (1)	1	,147,676			D (2)					
Common Stock, \$0.0075 par value per	share (1)	1	,103,314			D (3)					
Table II - Derivative Securities Benefic  1. Title of Derivative Security 2. Date Exercisable and Expiration Date (Month/Day/Year)			3. Title and Amount of Securiti Underlying Derivative Security		of Securities	4. Conversion or Exercise	5. Ownershi Form of	6. Nature of Indirect Beneficia Ownership			
(Instr. 4) and Expiration (Month/Day/Year)  Date		ion Date ear) Expiration	Underlying Derivative Secu (Instr. 4)  Amou			or Exercise Price of Derivative Security		Ownership (Instr. 5)			
					Shares		(Instr. 5)				
Series X Convertible Preferred Stock	<u>(4)</u>	(4)	Common S \$0.0075 pa value per s	ır	2,313,00	0 \$ (4)	D (2)				
Series X Convertible Preferred Stock	(4)	<u>(4)</u>	Common S \$0.0075 pa value per s	ır	1,506,00	0 \$ (4)	D (3)				
Series Y Convertible Preferred Stock	(5)	(5)	Common S \$0.0075 pa value per s	ır	655,959	\$ <sup>(5)</sup>	D (2)				
Series Y Convertible Preferred Stock	(5)	(5)	Common S \$0.0075 pa value per s	ır	596,813	\$ <u>(5)</u>	D (3)				

## **Reporting Owners**

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
BVF GP HOLDINGS LLC 44 MONTGOMERY ST., 40TH FLOOR SAN FRANCISCO, CA 94104		X			
BVF I GP LLC 44 MONTGOMERY ST., 40TH FLOOR SAN FRANCISCO, CA 94104		X			
BVF II GP LLC 44 MONTGOMERY ST., 40TH FLOOR SAN FRANCISCO, CA 94104		Х			

### **Signatures**

BVF I GP LLC, By: BVF GP HOLDINGS LLC, its sole member, By: /s/ Mark N. Lampert, Chief Executive Officer		03/17/2020
**Signature of Reporting Person		Date
BVF II GP LLC, By: BVF GP HOLDINGS LLC, its sole member, By: /s/ Mark N. Lampert, Chief Executive Officer		03/17/2020
**Signature of Reporting Person		Date
BVF GP HOLDINGS LLC, By: /s/ Mark N. Lampert, Chief Executive Officer		03/17/2020
**Signature of Reporting Person		Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- This Form 3 is filed jointly by BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP") and BVF GP HOLDINGS LLC ("BVF GPH", and together with BVF GP and (1) BVF2 GP, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.
- (2) Securities owned directly by Biotechnology Value Fund, L.P. ("BVF"). As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF.
- (3) Securities owned directly by Biotechnology Value Fund II, L.P. ("BVF2"). As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2.
- The Series X Convertible Preferred Stock may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d), more than 19.99% of the shares of Common Stock outstanding immediately after giving effect to such exercise. The Series X Convertible Preferred Stock does not have an expiration date. The initial conversion price is \$4.03 and is subject to certain adjustments pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock.
- The Series Y Convertible Preferred Stock may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d), more than 50% of the shares of Common Stock outstanding immediately after giving effect to such exercise. The Series Y Convertible Preferred Stock does not have an expiration date. The initial conversion price is \$13.00 and is subject to certain adjustments pursuant to the Certificate of Designation of Preferences, Rights and Limitations of Series Y Convertible Preferred Stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.